Lilly partners with startup Fauna Bio to see if a squirrel’s hibernation could lead to new obesity drugs

Eli Lilly already has multiple obesity drug candidates in mid- and late-stage clinical development to pad its success with its GIP and GLP-1 drug Zepbound, but a new partnership revealed Thursday morning shows that its ambitions in the field extend well beyond this decade and next.

Click here to view original post

Advertisement — Advertise with Biotech Networks